Systemic lupus erythematosus B. epidemiology, pathology, and pathogenesis

Primer on the Rheumatic Diseases: Thirteenth Edition

Volumn , Issue , 2008, Pages 319-326

  Pisetsky, David S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68049109974     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68566-3_15     Document Type: Chapter

References (20)

1. Ward MM, Pyun E. Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995; 38:274-283.
2. Weening JJ, D'Agati VD, Schwartz MM, et al. The clas-sification of glomerulonephritis in systemic lupus erythe-matosus revisited. Kidney Int 2004;65:521-530.
3. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-550.
4. Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444-1454.
5. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.
6. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5: 987-995.
7. Pisetsky DS. Antibody responses to DNA in normal immunity and aberrant immunity. Clin Diagn Lab Immunol 1998;5:1-6.
8. Rönnblom L, Eloranta M-L, Alm GV. The type I inter-feron system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408-420.
9. Clancy RM, Kapur RP, Molad Y, et al. Immunohistologic evidence support apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004; 150:173-182.
10. Huerta PT, Kowal C, DeGiorgio LA, et al. Immunity and behavior: antibodies alter emotion Proc Natl Acad Sci USA 2006;103:678-683.
11. Lauwerys BR, Wakeland EK. Genetics of lupus nephritis. Lupus 2005;14:2-12.
12. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythema-tosus. Ann Rev Immunol 2004;22:431-456.
13. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19: 56-59.
14. Aringer M, Graninger WB, Stein G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-3169.
15. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythema-tosus. J Exp Med 2005;202:341-344.
16. Baechler E, Batliwalla FM, Karypis G, et al. Interferon-induction gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-2615.
17. Kirou KA, Lee C, George S, Louca K, et al. Activation of interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-1503.
18. Gilkeson GS, Pippen AMM, Pisetsky DS. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest 1995;95:1398-1402.
19. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-3026.
20. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349: 1499-1500.